Clinical Trials · NCT00964262
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Peptron, Inc.
- Enrollment
- 34
- Start date
- Aug 2009
- Locations
- 1 site, South Korea
- Primary endpoint
- To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection